The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, the gravity of unmet medical needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-bacterial compositions.

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, anti-viral antigen-based components, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. CRISPR nucleases, alcohol dehydrogenase compositions, and genetically modified fusion polypeptides are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-bacterial compositions, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Anti-bacterial compositions is a key innovation area in pharmaceutical

Anti-bacterials are the subclass of antibiotics that kill or suppress the growth or reproducing ability of bacteria, which act by inhibiting cell wall synthesis, increasing cell membrane permeability, and interfering with their metabolism. Penicillin, cephalosporins, aminoglycosides, and macrolides are some of the examples of antibiotics/antibacterials.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 140+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-bacterial compositions.

Key players in anti-bacterial compositions – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to anti-bacterial compositions

Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies
GSK 1228 Unlock company profile
Johnson & Johnson 215 Unlock company profile
Sanofi 177 Unlock company profile
Pfizer 135 Unlock company profile
Zoetis 124 Unlock company profile
Qu Biologics 109 Unlock company profile
U.S. Department of Defense 87 Unlock company profile
Sanaria 85 Unlock company profile
C. H. Boehringer Sohn 83 Unlock company profile
Bharat Biotech 64 Unlock company profile
Otsuka Holdings 60 Unlock company profile
Children's Medical Center 59 Unlock company profile
Inovio Pharmaceuticals 57 Unlock company profile
Merck & Co 55 Unlock company profile
Molecular Templates 52 Unlock company profile
Zydus Lifesciences 50 Unlock company profile
Sequoia Vaccines 48 Unlock company profile
Gilead Sciences 47 Unlock company profile
Curevac 46 Unlock company profile
Henry M. Jackson Foundation for the Advancement of Military Medicine 44 Unlock company profile
United States Of America 44 Unlock company profile
Sentinext Therapeutics Sdn Bhd 43 Unlock company profile
Artificial Cell Technologies 41 Unlock company profile
Vaximm 41 Unlock company profile
Adjuvance Technologies 38 Unlock company profile
Scandinavian Biopharma Holding 36 Unlock company profile
Takeda Pharmaceutical 36 Unlock company profile
Centre National de la Recherche Scientifique 35 Unlock company profile
Panacea Biotec 35 Unlock company profile
Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung 34 Unlock company profile
Regeneron Pharmaceuticals 31 Unlock company profile
Optimus Holding Company 30 Unlock company profile
Elanco Animal Health 29 Unlock company profile
Eurofins Scientific 27 Unlock company profile
Cleveland Clinic Foundation 26 Unlock company profile
Leidos Holdings 25 Unlock company profile
VLP Therapeutics 24 Unlock company profile
The Henry M Jackson Foundation for the Advancement of Military Medicine 24 Unlock company profile
IMV 23 Unlock company profile
Institut Pasteur 22 Unlock company profile
Shin Nippon Biomedical Laboratories 22 Unlock company profile
Meiji Holdings 21 Unlock company profile
Eidgenossische Technische Hochschule Zurich 21 Unlock company profile
Epitopix 21 Unlock company profile
Statens Serum Institut 20 Unlock company profile
Precigen 20 Unlock company profile
Morishita Jintan 20 Unlock company profile
United States Army Reserve 20 Unlock company profile
CJ 19 Unlock company profile
Administrators of Tulane Educational Fund 17 Unlock company profile

Source: GlobalData Patent Analytics

GSK is one of the leading patent filers in anti-bacterial compositions. It recently entered an exclusive licence agreement with Spero Therapeutics for the development of Spero’s late-stage antibiotic asset, tebipenem HBr. The company has reported positive data from a Phase II clinical trial of investigational antitubercular agent, GSK3036656, to treat patients with drug-susceptible pulmonary tuberculosis. According to the trial data, the drug GSK3036656 was found to be well tolerated and demonstrated EBA with a low, once-a-day oral dose.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.